Astellas Pharma Inc. (ALPMF)
USD 10.12
(0.0%)
USD 10.12
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | 25.51 Billion JPY | -80.82% |
| 2023 | 133.02 Billion JPY | -14.55% |
| 2022 | 155.68 Billion JPY | 14.43% |
| 2021 | 136.05 Billion JPY | -44.24% |
| 2020 | 243.99 Billion JPY | 0.03% |
| 2019 | 243.91 Billion JPY | 14.37% |
| 2018 | 213.25 Billion JPY | -18.24% |
| 2017 | 260.83 Billion JPY | 4.76% |
| 2016 | 248.98 Billion JPY | 34.11% |
| 2015 | 185.66 Billion JPY | 58.95% |
| 2014 | 116.8 Billion JPY | -24.09% |
| 2013 | 153.86 Billion JPY | 16.99% |
| 2012 | 131.51 Billion JPY | 10.35% |
| 2011 | 119.18 Billion JPY | -36.06% |
| 2010 | 186.4 Billion JPY | -25.55% |
| 2009 | 250.39 Billion JPY | -9.25% |
| 2008 | 275.9 Billion JPY | 44.82% |
| 2007 | 190.51 Billion JPY | -1.3% |
| 2006 | 193.02 Billion JPY | 77.26% |
| 2005 | 108.89 Billion JPY | 7.85% |
| 2004 | 100.96 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 5.22 Billion JPY | -88.59% |
| 2024 Q3 | 18.96 Billion JPY | 263.07% |
| 2024 Q4 | 37.72 Billion JPY | 98.93% |
| 2024 Q1 | 45.79 Billion JPY | 194.91% |
| 2024 FY | 178.07 Billion JPY | 33.86% |
| 2023 Q2 | 86.74 Billion JPY | 161.69% |
| 2023 Q3 | 61.38 Billion JPY | -29.23% |
| 2023 Q4 | -48.25 Billion JPY | -178.6% |
| 2023 FY | 133.02 Billion JPY | -14.55% |
| 2023 Q1 | 33.14 Billion JPY | 342.21% |
| 2022 Q4 | -13.68 Billion JPY | -117.28% |
| 2022 FY | 155.68 Billion JPY | 14.43% |
| 2022 Q1 | 36.09 Billion JPY | 254.11% |
| 2022 Q2 | 54.07 Billion JPY | 49.84% |
| 2022 Q3 | 79.2 Billion JPY | 46.46% |
| 2021 Q3 | 72.59 Billion JPY | 178.6% |
| 2021 Q4 | -23.41 Billion JPY | -132.26% |
| 2021 FY | 136.05 Billion JPY | -44.24% |
| 2021 Q1 | 60.81 Billion JPY | 860.29% |
| 2021 Q2 | 26.05 Billion JPY | -57.15% |
| 2020 Q4 | 6.33 Billion JPY | -91.61% |
| 2020 FY | 243.99 Billion JPY | 0.03% |
| 2020 Q2 | 85.11 Billion JPY | 10.41% |
| 2020 Q3 | 75.46 Billion JPY | -11.34% |
| 2020 Q1 | 77.08 Billion JPY | 123.17% |
| 2019 Q1 | 63.54 Billion JPY | 89.66% |
| 2019 FY | 243.91 Billion JPY | 14.37% |
| 2019 Q2 | 63.29 Billion JPY | -0.4% |
| 2019 Q3 | 82.52 Billion JPY | 30.39% |
| 2019 Q4 | 34.54 Billion JPY | -58.15% |
| 2018 Q3 | 83.67 Billion JPY | 59.24% |
| 2018 FY | 213.25 Billion JPY | -18.24% |
| 2018 Q1 | 43.52 Billion JPY | 47.35% |
| 2018 Q2 | 52.54 Billion JPY | 20.72% |
| 2018 Q4 | 33.5 Billion JPY | -59.96% |
| 2017 Q4 | 29.54 Billion JPY | -60.2% |
| 2017 Q3 | 74.23 Billion JPY | 15.64% |
| 2017 FY | 260.83 Billion JPY | 4.76% |
| 2017 Q2 | 64.19 Billion JPY | -30.88% |
| 2017 Q1 | 92.86 Billion JPY | 178.15% |
| 2016 FY | 248.98 Billion JPY | 34.11% |
| 2016 Q1 | 61.91 Billion JPY | 158.15% |
| 2016 Q4 | 33.38 Billion JPY | -59.76% |
| 2016 Q3 | 82.96 Billion JPY | 17.3% |
| 2016 Q2 | 70.72 Billion JPY | 14.24% |
| 2015 Q1 | 50.56 Billion JPY | 277.96% |
| 2015 Q2 | 52.62 Billion JPY | 4.07% |
| 2015 Q3 | 58.49 Billion JPY | 11.16% |
| 2015 FY | 185.66 Billion JPY | 58.95% |
| 2015 Q4 | 23.98 Billion JPY | -59.0% |
| 2014 Q1 | 38.54 Billion JPY | 104.78% |
| 2014 Q3 | 83.32 Billion JPY | 81.13% |
| 2014 Q2 | 46 Billion JPY | 19.35% |
| 2014 FY | 116.8 Billion JPY | -24.09% |
| 2014 Q4 | -28.41 Billion JPY | -134.1% |
| 2013 Q2 | 35.49 Billion JPY | -32.88% |
| 2013 Q3 | 46.65 Billion JPY | 31.44% |
| 2013 Q4 | 18.82 Billion JPY | -59.66% |
| 2013 FY | 153.86 Billion JPY | 16.99% |
| 2013 Q1 | 52.89 Billion JPY | 452.96% |
| 2012 FY | 131.51 Billion JPY | 10.35% |
| 2012 Q1 | 48.8 Billion JPY | 2695.8% |
| 2012 Q2 | 34.19 Billion JPY | -29.92% |
| 2012 Q4 | -14.98 Billion JPY | -123.6% |
| 2012 Q3 | 63.5 Billion JPY | 85.7% |
| 2011 Q3 | 53.13 Billion JPY | 356.13% |
| 2011 Q2 | 11.65 Billion JPY | -79.3% |
| 2011 Q1 | 56.27 Billion JPY | 1385.87% |
| 2011 FY | 119.18 Billion JPY | -36.06% |
| 2011 Q4 | -1.88 Billion JPY | -103.54% |
| 2010 Q3 | 53.3 Billion JPY | -11.39% |
| 2010 FY | 186.4 Billion JPY | -25.55% |
| 2010 Q4 | 3.78 Billion JPY | -92.9% |
| 2010 Q1 | 69.16 Billion JPY | 136.55% |
| 2010 Q2 | 60.15 Billion JPY | -13.03% |
| 2009 FY | 250.39 Billion JPY | -9.25% |
| 2009 Q2 | 63.05 Billion JPY | 0.0% |
| 2009 Q3 | 89.8 Billion JPY | 42.42% |
| 2009 Q4 | 29.23 Billion JPY | -67.44% |
| 2008 FY | 275.9 Billion JPY | 44.82% |
| 2007 FY | 190.51 Billion JPY | -1.3% |
| 2006 FY | 193.02 Billion JPY | 77.26% |
| 2005 FY | 108.89 Billion JPY | 7.85% |
| 2004 FY | 100.96 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | -211.461% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | -47.999% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | -263.711% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 64325.31% |
| Novartis AG | 9.76 Billion USD | -161.214% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 99.296% |